BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. May 7, 2026; 32(17): 116590
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.116590
Niu Huang mitigates dextran sulfate sodium-induced colitis by modulating farnesoid X receptor activation and the complement 3/NLRP3 signaling pathway
Juan Shi, Chong-Yang Ma, Xiao-Hui Zhang, Kun-Jing Liu, Jin-Ying Liu, Qing-Guo Wang, Xue-Qian Wang, Fa-Feng Cheng, Tian Xu
Juan Shi, Tian Xu, Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
Juan Shi, Chong-Yang Ma, Xiao-Hui Zhang, School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
Kun-Jing Liu, Qing-Guo Wang, Xue-Qian Wang, Fa-Feng Cheng, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
Jin-Ying Liu, College of Traditional Chinese Medicine, Chengde Medical University, Chengde, Chengde 067000, Hebei Province, China
Co-first authors: Juan Shi and Chong-Yang Ma.
Co-corresponding authors: Fa-Feng Cheng and Tian Xu.
Author contributions: Shi J and Ma CY performed the research and wrote the original draft, they contributed equally to this article, they are the co-first authors of this manuscript; Zhang XH, Liu KJ, and Liu JY acquired and analyzed the data; Wang QG and Wang XQ developed methodology; Ma CY, Liu JY, and Xu T acquired funding; Cheng FF and Xu T designed the research study, participated in review and editing, they contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors have read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 82374165, No. 82405050, and No. 82004327; Fundamental Research Funds for the Central Universities, China, No. 3332024017; and Research Project of Hebei Provincial Administration of Traditional Chinese Medicine, No. 2025086.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of Capital Medical University, approval No. AEEI-2024-007.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: All data in the research will be made available on request.
Corresponding author: Tian Xu, Postdoc, Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China. xutian@pumch.cn
Received: November 18, 2025
Revised: January 7, 2026
Accepted: February 12, 2026
Published online: May 7, 2026
Processing time: 160 Days and 17.4 Hours
Core Tip

Core Tip: This study demonstrates that Niu Huang effectively alleviates ulcerative colitis. By identifying its active components and employing transcriptomic and proteomic sequencing to predict mechanisms, this study reveals that this drug exerts anti-colitis effects by activating the farnesoid X receptor (FXR), which subsequently inhibits nuclear factor kappa B transcription. This inhibition reduces the accumulation of complement component 3 and suppresses excessive activation of the NOD-like receptor family pyrin domain containing 3 inflammasome in colon tissue, alleviating intestinal inflammation. The critical role of FXR was conclusively validated using both FXR antagonist guggulsterone and Fxr-knockout mouse models.